JP2023536437A - 小胞体アミノペプチダーゼ２（ｅｒａｐ２）媒介性免疫応答の調節 - Google Patents

小胞体アミノペプチダーゼ２（ｅｒａｐ２）媒介性免疫応答の調節 Download PDF

Info

Publication number
JP2023536437A
JP2023536437A JP2023504833A JP2023504833A JP2023536437A JP 2023536437 A JP2023536437 A JP 2023536437A JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023536437 A JP2023536437 A JP 2023536437A
Authority
JP
Japan
Prior art keywords
hla
subject
nucleic acid
disease
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536437A5 (https=
Inventor
ゲルフマン、サハル
リゴツキ、アン
コッポラ、ジョバンニ
バラス、アリス
モスカーティ、アーデン
エイ． スタール、エリ
エイ． コスミツキ、ジャック
アレン レベズ フェレイラ、マヌエル
ロマーノ、カーメロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023536437A publication Critical patent/JP2023536437A/ja
Publication of JP2023536437A5 publication Critical patent/JP2023536437A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
JP2023504833A 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ２（ｅｒａｐ２）媒介性免疫応答の調節 Pending JP2023536437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063056562P 2020-07-25 2020-07-25
US63/056,562 2020-07-25
US202163171672P 2021-04-07 2021-04-07
US63/171,672 2021-04-07
PCT/US2021/043062 WO2022026336A1 (en) 2020-07-25 2021-07-23 Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Publications (2)

Publication Number Publication Date
JP2023536437A true JP2023536437A (ja) 2023-08-25
JP2023536437A5 JP2023536437A5 (https=) 2024-07-30

Family

ID=77564145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504833A Pending JP2023536437A (ja) 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ２（ｅｒａｐ２）媒介性免疫応答の調節

Country Status (10)

Country Link
US (1) US20230059929A1 (https=)
EP (1) EP4188963A1 (https=)
JP (1) JP2023536437A (https=)
KR (1) KR20230043888A (https=)
CN (1) CN116194484A (https=)
AU (1) AU2021316196B2 (https=)
CA (1) CA3189755A1 (https=)
IL (1) IL299986A (https=)
MX (1) MX2023001059A (https=)
WO (1) WO2022026336A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4416286A1 (en) 2021-10-14 2024-08-21 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US12613286B2 (en) 2024-01-22 2026-04-28 Garrett Transportation I Inc. System and method for battery parameter recharacterization
CN118593462B (zh) * 2024-06-28 2026-01-27 沈阳药科大学 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEORGIADIS, D. ET AL.: "Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application", CURRENT MEDICINAL CHEMISTRY, vol. 26, no. 15, JPN6025040891, 2019, pages 2715 - 2729, ISSN: 0005703047 *
KUIPER, J. J. ET AL.: "A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot cho", HUMAN MOLECULAR GENETICS, vol. 23, no. 22, JPN6025040894, 2014, pages 6081 - 6087, ISSN: 0005703045 *
KUO, I. C. ET AL.: "Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcin", ONCOTARGET, vol. 8, no. 37, JPN6025040896, 2017, pages 61698 - 61708, ISSN: 0005703044 *
ZERVOUDI, E. ET AL.: "Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentati", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, no. 49, JPN6025040892, 2013, pages 19890 - 19895, ISSN: 0005703046 *

Also Published As

Publication number Publication date
AU2021316196A1 (en) 2023-02-23
IL299986A (en) 2023-03-01
CN116194484A (zh) 2023-05-30
EP4188963A1 (en) 2023-06-07
AU2021316196B2 (en) 2025-09-25
MX2023001059A (es) 2023-04-26
WO2022026336A1 (en) 2022-02-03
CA3189755A1 (en) 2022-02-03
US20230059929A1 (en) 2023-02-23
KR20230043888A (ko) 2023-03-31

Similar Documents

Publication Publication Date Title
US20250375519A1 (en) Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes
JP2023536437A (ja) 小胞体アミノペプチダーゼ２（ｅｒａｐ２）媒介性免疫応答の調節
US11359246B2 (en) Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
JP2026004359A (ja) Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療
US20230025756A1 (en) Induction of regulatory b cells for the treatment of immune-mediated diseases
RU2858837C2 (ru) Модуляция иммунного ответа, опосредованного аминопептидазой 2 эндоплазматического ретикулума (erap2)
US20230000897A1 (en) Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents
US12157891B2 (en) Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
US20240084298A1 (en) Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors
US12577562B2 (en) Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors
Xu et al. Association of the porcine cluster of differentiation 4 gene with T lymphocyte subpopulations and its expression in immune tissues
US20230027007A1 (en) Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
CN118613584A (zh) 使用内质网氨基肽酶1(erap1)抑制剂治疗葡萄膜炎
CN117940565A (zh) 用Wnt家族成员5B(WNT5B)抑制剂治疗骨矿物质密度降低
KR20230152732A (ko) 링 핑거 단백질 213(rnf213) 억제제를 이용한 간 질환의 치료

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106